anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This project examines individual health decisions that occur within these structural environments, describing their accumulated impact on key pregnancy outcomes and care indicators related to three themes: vaccination, perinatal care, social supports and mental health. The decisions made during pregnancy have longitudinal impacts on the life of the pregnant person, future child, and family.(1) Given evidence of the particularly difficult situations faced by pregnant people, and the importance of these health decisions, it is important to understand how pandemic circumstances have shaped health decision-making. Understanding how and why pregnant people are making health decisions allows for better clinical and social support as the pandemic endures, and will inform future policy planning. This project is a cross-provincial, parallel mixed-methods study, with thematic data integration at the design and interpretation stages. Ontario and British Columbia were chosen as the two provinces of study because they both experienced a significant impact from COVID-19, both have access to comprehensive administrative health data, and a large number of live births each year.

This study was funded in late February 2022. The quantitative cohort creation plans and data access requests were finalized in late Fall 2022. Qualitative data collection was piloted in Summer 2022, data collection was complete in both provinces August 2023. Study completion is anticipated for February 2024.
The patient should be told to:

  1. Use the medication for the full treatment time even though symptoms may have improved and notify the physician if there is no improvement after four weeks. 
  2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible sensitization. 
  3. Avoid the use of occlusive wrappings or dressings.
To demonstrate that α4β2\* nAChRs are appropriate therapeutic targets in Parkinson's Disease (PD), it is necessary to study key pharmacokinetic-pharmacodynamic features of α4β2\* nAChR in the context of the PD brain with loss of nerve cells that produce the neurotransmitter acetylcholine, a pathologic environment in which they may exhibit unique features. This personalized medicine approach focuses our studies on the subgroup of PD subjects with loss of nerve cells that produce the neurotransmitter acetylcholine identified by Project II and the Clinical Resource Core. The investigators will assess α4β2\* nAChR features using PET imaging with the α4β2\* nAChR ligand \[18-Fluorine\]flubatine, subacute administration of the α4β2\* nAChR partial agonist Varenicline (VCN), and laboratory measures of gait, balance, and attention. The investigators will use \[18-Fluorine\] flubatine PET to assess VCN occupancy of brain α4β2\* nAChRs (experiments 1 \& 2). VCN will be administered to both PD participants (experiment 1) and healthy controls (experiment 2) and both populations will undergo a flubatine PET scan to assess VCN occupancy. Using this PET data to select an appropriate VCN dose, the investigators will perform a pharmacodynamic study (experiment 3) with subacute VCN administration to determine if α4β2\* nAChR stimulation improves laboratory measures of gait function, postural control, and attentional function in PD subjects with loss of nerve cells that produce the neurotransmitter acetylcholine.
ETHNOPHARMACOLOGICAL RELEVANCE: Wikstroemia indica (L.) C. A. Mey. is traditionally used for the treatment of gastrointestinal disorders, respiratory illnesses, skin infections, and inflammatory conditions. Despite extensive evidence of its biological potential, including antipyretic, antimicrobial, antifungal, anti-inflammatory, and diuretic properties, there are currently no reports indicating its analgesic effects.
AIM OF THE STUDY: Crude extracts from W. indica stems were examined for anti-nociceptive activity. Additionally, an in-depth investigation was conducted to uncover the molecular basis for the possible analgesic phenomenon.
MATERIALS AND METHODS: W. indica stems were subjected to ethanol extraction. To evaluate the in vivo analgesic activity, both chemical and physical-induced pain models were employed. Additionally, single-cell electrophysiological recordings were performed on human embryonic kidney 293T (HEK293T) cells expressing NaV1.7 channel.
RESULTS: Crude extracts derived from W. indica exhibited significant efficacy in mitigating the pain sensation, as evidenced by their substantial effects in both acetic acid-induced and heat-induced pain models. Further screening unveiled osthenol as a key bioactive compound responsible for mediating the analgesic properties of W. indica. Osthenol directly interacts with the pore domain of NaV1.7 channels, leading to channel inhibition. Importantly, this interaction is independent of any changes in the channel gating modifier domain.
CONCLUSION: Both W. indica and osthenol demonstrate potential as effective anti-nociceptive agents in preclinical studies. Their analgesic effects are likely achieved by inhibiting the NaV1.7 channel, which is crucial in pain initiation, transmission, and modulation. These results elucidate the molecular basis of the W. indica as a pain-relieving medication. Additionally, osthenol holds great potential in advancing the development of anti-nociceptive drugs targeting the NaV1.7 channel.
The invention discloses a polypeptide drug and application thereof in treating type 2 diabetes and non-alcoholic fatty liver, wherein the amino acid sequence of the polypeptide drug comprises at least one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 and SEQ ID NO. 5, and the polypeptide drug is used as an agonist for targeting GPRC6A protein receptor, can activate the GPRC6A protein receptor on the surface of islet beta cells, stimulates division of islet beta cells and secretes insulin so as to recover the functions of islet beta cells. Meanwhile, the polypeptide medicine can stimulate catabolism of liver fat, and is helpful for nonalcoholic fatty liver diseases.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use, having melanogenesis suppressing action and effective against pigmentation, stain, freckle, chloasma, etc., after sun burn by using a specific compound obtained by extracting from a plant, etc., of the family Zingiberaceae, etc., as an active ingredient. SOLUTION: This skin preparation for external use is obtained by using a compound represented by the formula (R<1> and R<2> are each H or methyl). The compound of the formula is obtained by immersing Lempuyang which is a plant of the genus Zingiber of the family Zingiberaceae into a solvent or heating the plant under reflux together with the extracting solvent, filtering the mixture, concentrating the solution and purifying the concentrate by a silica gel column chromatography. The blend amount of the compound of the formula is preferably 0.001-20.0wt.%, especially preferably 0.1-7.0wt.%. The skin preparation for external use is preferably prepared into a form such as cream, ointment, gel, lotion, emulsion, stick, pack or solution. The skin preparation for external use is excellent also in safety.
Alzheimer's disease (AD) is the most common form of dementia. Obesity in middle age increases AD risk and severity, which is alarming given that obesity prevalence peaks at middle age and obesity rates are accelerating worldwide. Midlife, but not late-life obesity increases AD risk, suggesting that this interaction is specific to preclinical AD. AD pathology begins in middle age, with accumulation of amyloid beta (Aβ), hyperphosphorylated tau, metabolic decline, and neuroinflammation occurring decades before cognitive symptoms appear. We used a transcriptomic discovery approach in young adult (6.5 months old) male and female TgF344-AD rats that overexpress mutant human amyloid precursor protein and presenilin-1 and wild-type (WT) controls to determine whether inducing obesity with a high-fat/high-sugar "Western" diet during preclinical AD increases brain metabolic dysfunction in dorsal hippocampus (dHC), a brain region vulnerable to the effects of obesity and early AD. Analyses of dHC gene expression data showed dysregulated mitochondrial and neurotransmission pathways, and up-regulated genes involved in cholesterol synthesis. Western diet amplified the number of genes that were different between AD and WT rats and added pathways involved in noradrenergic signaling, dysregulated inhibition of cholesterol synthesis, and decreased intracellular lipid transporters. Importantly, the Western diet impaired dHC-dependent spatial working memory in AD but not WT rats, confirming that the dietary intervention accelerated cognitive decline. To examine later consequences of early transcriptional dysregulation, we measured dHC monoamine levels in older (13 months old) AD and WT rats of both sexes after long-term chow or Western diet consumption. Norepinephrine (NE) abundance was significantly decreased in AD rats, NE turnover was increased, and the Western diet attenuated the AD-induced increases in turnover. Collectively, these findings indicate obesity during prodromal AD impairs memory, potentiates AD-induced metabolic decline likely leading to an overproduction of cholesterol, and interferes with compensatory increases in NE transmission.
Embodiments of the present disclosure relates to a method and system for enabling automated health assessment. The method receives values of health related measurable parameters associated with a user and assigns a weightage score based on age and importance of the measurable parameters. The method also determines a parameter score corresponding to each parameter. Based on the weightage and parameter score, a health score of the user is determined for further recommendation of wellness programs suitable for the user. Thus, present disclosure enables measurement of a user's health related parameters and determines health score to indicate level of health thereby enabling a health coach to recommend one or more wellness programs suitable to the user for preventive health care. The system comprises a dedicated web-based and mobile-based application to effectively capture the measured information and constantly apprise and advise health status of the person at any point of time.
Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity. DCs have been historically considered as the most effective and potent cell population to capture, process and present antigens to activate naïve T cells and originate favorable immune responses in many diseases, such as cancer. However, in the last decades, it has been observed that DCs not only promote beneficial responses, but also drive the initiation and progression of some pathologies, including inflammatory bowel disease (IBD). In line with those notions, different therapeutic approaches have been tested to enhance or impair the concentration and role of the different DC subsets. The blockade of inhibitory pathways to promote DCs or DC-based vaccines have been successfully assessed in cancer, whereas the targeting of DCs to inhibit their functionality has proved to be favorable in IBD. In this review, we (a) described the general role of DCs, (b) explained the DC subsets and their role in immunogenicity, (c) analyzed the role of DCs in cancer and therapeutic approaches to promote immunogenic DCs and (d) analyzed the role of DCs in IBD and therapeutic approaches to reduced DC-induced inflammation. Therefore, we aimed to highlight the "yin-yang" role of DCs to improve the understand of this type of cells in disease progression.
An electronic device and a method of training a classification model for age-related macular degeneration (AMD) are provided. The method includes the following steps. Training data is obtained. A loss function vector corresponding to the training data is calculated based on a machine learning algorithm, in which the loss function vector includes a first loss function value corresponding to a first classification of AMD and a second loss function value corresponding to a second classification of AMD, the first classification corresponds to a first group, and the second classification corresponds to one of the first group and a second group. The first loss function value is updated according to the second loss function value and a group penalty weight in response to the second classification corresponding to the second group to generate an updated loss function vector. The classification model is trained according to the updated loss function vector.
INTRODUCTION: There is still a lack of information on the role of Tranexamic acid (TXA) in total ankle arthroplasty (TAA). The purpose of this study is to comprehensively review, consolidate, and analyze findings from existing research on the effectiveness and safety of TXA in TAA.
MATERIALS AND METHODS: The comprehensive literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) using PubMed, Embase, Web of Science, and Cochrane databases, for original, English-language studies investigating the efficacy and safety of TXA in TAA, through February 2023. Evaluated data for the meta-analysis included estimated blood loss (EBL), change in perioperative hemoglobin, need for transfusion, and complications including DVT/PE, and wound complications.
RESULTS: A total of nine studies were included in this study. In total, 450 TAA were included, with 244 receiving TXA (54.2%) and 206 not receiving TXA (45.8%). TXA in TAA significantly decreased EBL. A significantly lower rate of wound complications in the TXA group with the relative risk (RR) of 0.51. We classified wound complications into wound infection and delayed wound healing/dehiscence. A significant decrease in the rate of wound infection and a tendency showing a decrease in the rate of delayed wound healing/dehiscence in the TXA group were noted: the RR of 0.29, and 0.63, respectively. TXA did not increase the incidence of DVT/PE following TAA.
CONCLUSIONS: In conclusion, the utilization of TXA during TAA demonstrated a statistically significant reduction in EBL and relative risk for wound complications. However, further RCTs with larger sample sizes will be necessary to establish a more robust conclusion regarding the efficacy and safety of TXA in TAA.
LEVEL OF EVIDENCE: Level III, systematic review and meta-analysis.
The present invention relates to a compound Jigucao capsule for treating the liver and the gallbladder diseases, which comprises abrus herb 240, oriental wormwood 40, cape jasmine fruit 32, white peony alba 40, Chinese magnolivine fruit 40, notoginseng 16, barbary wolfberry fruit 16, artificial bezoar 4 and pearl layer powder 4 by weight parts. The present invention has the following manufacturing process: the Chinese magnolivine fruit is leached by 70% of alcohol to collect filter liquid. In addition, the abrus herb, the oriental wormwood, the cape jasmine fruit, the white peony alba and the barbary wolfberry fruit are decocted with water to collect the filter liquid. The filter liquid is combined into the extracting liquid of schizandrol and is condensed into a thick paste shape. After the filter liquid, the notoginseng fine powder, the artificial bezoar and the pearl layer powder are uniformly mixed, dried and pulverized, the mixtures are separately placed into capsules, and accordingly, the compound Jigucao capsule is formed. The compound Jigucao capsule of the present invention has obvious and stable treating effects on dampness and heat diseases in the liver and the gallbladder and viral liver and gallbladder diseases. The compound Jigucao capsule can be administered for a long time without side effects, and the compound Jigucao capsule also has favorable treating effects on obstinate liver diseases, such as chronic hepatitis b, etc. The present invention has the advantages of simple production technique, convenient administration and low price.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-bome virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Here, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene (GPC) of the laboratory CCHFV strain CCHFV-IbAr 10200 (CCHFV-M10200). Increasing the dose of CCHFV-M 10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant, heterologous CCHFV- Afg09-2990 strain. We also report complete protection from CCHFV - Afg09-2990 challenge following vaccination with a CCHFV- Afg09-2990 GPC expressing DNA vaccine (CCHFV -M Afgog). Finally, we show that the non-stmctural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M- segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.
The invention provides isolated non-selective cation channel proteins which are (a) activatable by noxious heat; (b) obtainable from human T lymphocytes; (c) not capsaicin sensitive, particularly the VR-L protein (Seq ID No. 2), plus or variants (e.g. homologues or fragments) thereof. Also provided are nucleic acids encoding these (e.g. Seq ID No. 1), or which have utility in probing, amplifying or down-regulating these. Methods of providing the proteins and nucleic acids are disclosed, as are vectors, host cells, and organisms utilising them, and antibodies. Also disclosed are methods of influencing the electrophysiological and/or pharmacological properties of a cell (e.g. by way of therapy) based on manipulation of the proteins or nucleic acids, and methods for screening for substances having ion-channel modulating activity (which may be potential analgesics or other compounds which affect nociception, immunomodulatory agents or neuromodulatory agents).
Preclinical data suggest that concomitant inhibition of two non-redundant amplified pathways (mTOR and EGFR) can reverse drug resistance and more profoundly affect tumor growth than targeting either pathway alone. EGFR inhibitors may abrogate feedback loops that stimulate upstream signaling events such as PI3K and Akt in the face of mTOR inhibition. Although ErbB receptors signal through mTOR-dependent mechanisms, mTOR-independent ErbB receptor signaling also occurs in cancer. Furthermore, deregulation of apoptotic pathways like the PI3K/Akt/PTEN axis (e.g. via PTEN loss of function or AKT gene amplification) may lead to resistance to EGFR inhibitors. Treatment with an inhibitor of mTOR may reverse this resistance. Targeting the mTOR and EGFR pathways concurrently may more effectively inhibit tumor growth than inhibiting either pathway alone.

The compelling preclinical data, coupled with modest single agent activity seen with EGFR inhibition and mTOR inhibition in neuroendocrine tumors (NETs), provides a strong rationale for studying the activity of concomitant pathway inhibition in patients with advanced NETs. Support for this strategy also stems from the fact that EGFR inhibitors can be safety combined with mTOR inhibitors in humans. Emerging data from a phase I study of RAD001 plus erlotinib in patients with previously treated advanced non-small cell lung cancer (NSCLC) suggests that the two agents can be safely combined at the following doses: RAD001 5 mg PO q D and erlotinib 150 mg PO qD.

Of note, the original dose selections for RAD001 and erlotinib for this study stem directly from phase I studies with this combination (RAD001 5 mg PO qD plus erlotinib 150 mg PO qD). The modified dose selections (RAD001 5 mg PO qD plus erlotinib 100 mg PO qD) are the result of integrating discussions with the study sponsor, preliminary safety data from the first few patients enrolled in this study (suggesting that some patients tolerate full-dose therapy and others do not) and additional phase I data suggesting that the maximum tolerated dose (MTD) in some patient populations is lower than in others, e.g. the MTD in breast cancer patients is RAD001 2.5 mg PO qD and erlotinib 100 mg PO QD (Mayer et al. American Society of Clinical Oncology (ASCO) 2009 Breast Cancer Symposium, Abstract #254).
Seizures occurred in 0.2% (4/2547) of olanzapine and fluoxetine -treated patients during open-label clinical studies. No seizures occurred in the controlled olanzapine and fluoxetine studies. Seizures have also been reported with both olanzapine and fluoxetine monotherapy. Olanzapine and fluoxetine should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold, e.g., Alzheimer's dementia. Olanzapine and fluoxetine is not approved for the treatment of patients with Alzheimer's disease. Conditions that lower the seizure threshold may be more prevalent in a population of ≥65 years of age.
A method is disclosed for sealing edible capsules comprised of telescopically engaged tubular capsule halves that define a junction seam between them. The method comprises adhesively applying against at least a portion of the seam a frangible, edible label adapted to cover the seam at the point of intersection therewith, and to fracture upon slight displacement of the capsule halves with respect to each other. In one embodiment, the present method comprises the preparation of individual labels, the application to such labels of a quantity of adhesive and the subsequent application of the labels to the capsule. In an alternate embodiment, the labels, comprising a film forming material, are directly applied to the capsule by the projection of a hot melt of the film forming material onto the capsule at the location of the seam. The method may be practiced by means of automated label applying machinery, in the instance of the prior preparation of the labels, and by jet printing techniques in the instance of direct label application. The labels may also be imprinted with suitable indicia, either before or after application to the capsule. The capsules sealed and labeled in accordance with the present method exhibit improved tamper evidence and resistance, as the labels are incapable of cosmetic reconstruction after tampering. In the instance where the label comprises a longitudinal strip extending annularly about the entire capsule seam, the resulting capsule is advantageously rendered fluid-tight.
The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population.  The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair.  Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells.  In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired.  As a result, compounds described herein are less toxic to nonselected cells.  Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like.
Breast cancers (BC) are rare in men and are often caused by constitutional predisposing factors. In women, mosaic BRCA1 promoter methylations (MBPM) are frequent events, detected in 4-8% of healthy subjects. This constitutional epimutation increases risk of early-onset and triple-negative BC. However, the role of MBPM in male BC predisposition has never been assessed. We screened 40 blood samples from men affected by BC, and performed extensive tumour analysis on MBPM-positive patients. We detected two patients carrying MBPM. Surprisingly, tumour analysis revealed that neither of these two male BCs were caused by the constitutional BRCA1 epimutations carried by the patients.